Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
O75604
UPID:
UBP2_HUMAN
Alternative names:
41 kDa ubiquitin-specific protease; Deubiquitinating enzyme 2; Ubiquitin thioesterase 2; Ubiquitin-specific-processing protease 2
Alternative UPACC:
O75604; B0YJB8; E9PPM2; Q8IUM2; Q8IW04; Q96MB9; Q9BQ21
Background:
Ubiquitin carboxyl-terminal hydrolase 2, known by alternative names such as 41 kDa ubiquitin-specific protease and Deubiquitinating enzyme 2, plays a pivotal role in cellular processes. It deubiquitinates polyubiquitinated target proteins like MDM2, MDM4, and CCND1, influencing cell-cycle progression and circadian rhythms. Its activity modulates the degradation of key regulatory proteins, indirectly affecting p53 activity and promoting G1/S cell-cycle progression in both normal and cancer cells. Additionally, it regulates Ca(2+) absorption in the small intestine by controlling the levels of NHERF4 and the activity of the Ca(2+) channel TRPV6.
Therapeutic significance:
Understanding the role of Ubiquitin carboxyl-terminal hydrolase 2 could open doors to potential therapeutic strategies.